ArticleThe EMBO journal2002
Dynamic interaction of CD2 with the GYF and the SH3 domain of compartmentalized effector molecules.
Article in The EMBO journal, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 89 citations in OpenAlex.
- Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2.Experimental & molecular medicine · 2024Review
- A molecular switch controls assembly of bacterial focal adhesions.Science advances · 2024Article
- Discovering common pathogenetic processes between tuberculosis and COVID-19 by bioinformatics and system biology approach.Heliyon · 2024Article
- Systematic discovery of protein interaction interfaces using AlphaFold and experimental validation.Molecular systems biology · 2024Article
- The nuclear GYF protein CD2BP2/U5-52K is required for T cell homeostasis.Frontiers in immunology · 2024Article
- Molecular basis for GIGYF-TNRC6 complex assembly.RNA (New York, N.Y.) · 2023Article
- Article
- Interaction between DLC-1 and SAO-1 facilitates CED-4 translocation during apoptosis in the Caenorhabditis elegans germline.Cell death discovery · 2022Article
- Emerging roles of spliceosome in cancer and immunity.Protein & cell · 2022Review
- Creativity comes from interactions: modules of protein interactions in plants.The FEBS journal · 2022Review
- Do polyproline II helix associations modulate biomolecular condensates?FEBS open bio · 2021Review
- Structural evidence for a proline-specific glycopeptide recognition domain in an O-glycopeptidase.Glycobiology · 2021Article
- CD2 Immunobiology.Frontiers in immunology · 2020Review
- Article
- TEG-1 CD2BP2 controls miRNA levels by regulating miRISC stability in C. elegans and human cells.Nucleic acids research · 2017Article
- Article
- Proline rich motifs as drug targets in immune mediated disorders.International journal of peptides · 2012Article
- Hole-in-one mutant phenotypes link EGFR/ERK signaling to epithelial tissue repair in Drosophila.PloS one · 2011Article
- Novel peptide-mediated interactions derived from high-resolution 3-dimensional structures.PLoS computational biology · 2010Article
- Proline-rich sequence recognition: I. Marking GYF and WW domain assembly sites in early spliceosomal complexes.Molecular & cellular proteomics : MCP · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Intracellular protein interaction domains are essential for eukaryotic signaling. In T cells, the CD2BP2 adaptor binds two membrane-proximal proline-rich motifs in the CD2 cytoplasmic tail via its GYF domain, thereby regulating interleukin-2 production. Here we present the structure of the GYF domain in complex with a CD2 tail peptide. Unlike SH3 domains, which use two surface pockets to accommodate proline residues of ligands, the GYF domain employs phylogenetically conserved hydrophobic residues to create a single interaction surface. NMR analysis shows that the Fyn but not the Lck tyrosine kinase SH3 domain competes with CD2BP2 GYF-domain binding to the same CD2 proline-rich sequence in vitro. To test the in vivo significance of this competition, we used co-immunoprecipitation experiments and found that CD2BP2 is the ligand of the membrane-proximal proline-rich tandem repeat of CD2 in detergent-soluble membrane compartments, but is replaced by Fyn SH3 after CD2 is translocated into lipid rafts upon CD2 ectodomain clustering. This unveils the mechanism of a switch of CD2 function due to an extracellular mitogenic signal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.